Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares
I'm PortAI, I can summarize articles.
Sands Capital Life Sciences Pulse Fund II, L.P. has acquired common shares of Inhibikase Therapeutics Inc. (IKT), as reported in a recent regulatory filing. The filing was submitted by Sands Capital Life Sciences Pulse Fund II, L.P. and other beneficial owners. This information was originally published by Inhibikase Therapeutics Inc. via the EDGAR system of the U.S. Securities and Exchange Commission.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments